meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
Apilimod
corticosteroids
Immunostimulants drugs
Immunosuppressants drugs
abatacept
adalimumab
anakinra
anti-interleukin-6
clazakizumab
Levilimab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
canakinumab
cenicriviroc
complement inhibitors
conestat alfa
ravulizumab
CRAC-channel inhibitors (auxora)
eculizumab
emapalumab
fostamatinib
infliximab
itolizumab
ixekizumab
jakotinib
janus kinase (JAK) inhibitor
baricitinib
baricitinib plus remdesivir
ruxolitinib
TD-0903
TD-0903 10mg
TD-0903 1mg
TD-0903 3mg
tofacitinib
lenzilumab
pamrevlumab
tacrolimus
tetrandrine
thalidomide
inhaled corticosteroids
Kinase inhibitors
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
thymosin
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
corticosteroids
dexamethasone
Immunosuppressants drugs
anti-interleukin-6
tocilizumab
antiviral and associated therapy
favipiravir
control
placebo
standard of care
Vitamins
vitamin C
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
corticosteroids: no
corticosteroids: yes
critical disease
severe disease
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded